Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 4.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.14 | - |
NAV | ₹30.80 | - |
Fund Started | 04 Dec 2015 | - |
Fund Size | ₹1213.92 Cr | - |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 39.38% | - |
3 Year | 21.53% | - |
5 Year | 27.37% | - |
1 Year
3 Year
5 Year
Equity | 95.72% | - |
Cash | 4.28% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.80% |
Aurobindo Pharma Ltd. | 7.71% |
Lupin Ltd. | 6.93% |
Cipla Ltd. | 6.19% |
Dr. Reddy's Laboratories Ltd. | 6.09% |
Divi's Laboratories Ltd. | 5.34% |
Fortis Healthcare Ltd. | 4.64% |
Zydus Lifesciences Ltd. | 3.75% |
Alkem Laboratories Ltd. | 3.50% |
Apollo Hospitals Enterprise Ltd. | 3.31% |
Name | Meeta Shetty | - |
Start Date | 09 Nov 2018 | - |
Name
Start Date
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | - |
Launch Date | 04 Dec 2015 | - |
Description
Launch Date